Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06735625
Recruiting Not applicable

Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"

NCT06735625 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-03-06
Last updated
2025-04-02

Condition(s) studied

in Relation to Sickle Cell Disease

Investigational drug(s) / intervention(s)

Measurement of AHSP concentration

Measurement of AHSP concentration: Pseudonymization and identification of research samples EDTA tube of 4 mL for patients over 15 and a half years old, and 2 EDTA tubes of 2 mL for children aged 3 to 15 and a half years, totaling 4 mL) by Team 4 according to the procedure in force at the URC. The 4 mL research sample will then be divided into 1 mL fractions by a technician in the laboratory and stored at -80°C in the medical biology laboratory.

Study summary

Evaluation of AHSP concentration in total blood as a biomarker in adult and pediatric sickle cell patients

Eligibility

Sex
ALL
Min age
3 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Inclusion Criteria for Sickle Cell Patients 1. Adults: \> 15 years and 6 months 2. Pediatrics: ≥ 3 years and ≤ 15 years and 6 months 3. Known SS or Sβ0 phenotypes Inclusion Criteria for Control Patients. 1 -Adults: \> 15 years and 6 months /Pediatrics: ≥ 3 years and ≤ 15 years and 6 months 2-Absence of Hemoglobinopathy 3-Follow-up for one of the following conditions (adults): Evaluation of hematological disease excluding hemoglobinopathy, evaluation of prolonged fever or inflammatory syndrome, initial or episodic evaluation of an auto-inflammatory disease or systemic disease, general health deterioration -Follow-up for one of the following conditions (pediatrics): Suspected precocious puberty, growth delay, or neurodevelopmental disorder 4-Blood sample planned as part of medical care Exclusion Criteria: 1. Hemoglobin disorder other than sickle cell disease (Criteria for Sickle Cell Patients) 2. Hemoglobinopathies other than sickle cell disease (Criteria for Control Patients) 3. Transfusion less than 3 months ago 4. Chronic active viral disease: hepatitis B, C, HIV 5. Current infections or known inflammatory pathologies 6. Known hyper or hypothyroidism or subject treated with levothyroxine 7. Active tumor pathology or remission for less than 5 years 8. Oral corticosteroid therapy in progress 9. Participation in interventional biomedical research 10. Opposition to participation in research by the patient if he is an adult, or by one of the two parents if the patient is a minor. 11. Non-affiliation to a social security system

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier de Saint-Denis Saint-Denis France Recruiting

More Centre Hospitalier de Saint-Denis trials in France

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06735625 on ClinicalTrials.gov ↗ ← All trials in France